BTK
Os inibidores da tirosina quinase de Bruton (BTK) são compostos que especificamente têm como alvo e inibem a BTK, uma enzima crucial envolvida na sinalização do receptor de células B e na regulação da angiogênese. A BTK desempenha um papel significativo na proliferação e sobrevivência de células cancerígenas, particularmente em malignidades hematológicas. Ao inibir a BTK, esses compostos podem interromper a angiogênese e o crescimento tumoral, tornando-os valiosos na terapia do câncer. Na CymitQuimica, oferecemos uma gama de inibidores de BTK de alta qualidade para apoiar sua pesquisa em oncologia, imunologia e angiogênese.
Foram encontrados 167 produtos para "BTK".
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CFON-026
CAS:CFON-026 is a selective, orally active, non-covalent BTK inhibitor with an IC50 of 0.27 nM. It demonstrates significant antitumor activity against wild-type BTK (TMD8 and REC-1) as well as all clinically relevant BTK resistance mutations (BTKC481S, T474I, L528W, and V416L). CFON-026 induces complete tumor regression in the TMD8 xenograft mouse model. This compound is applicable for research into hematologic cancers, such as chronic lymphocytic leukemia and Waldenström's macroglobulinemia.Fórmula:C33H34N8O2Peso molecular:574.68WS-11
CAS:WS-11 is a non-covalent reversible inhibitor of BTK, with IC50 values of 3.9 nM for the wild-type and 2.2 nM for the C481S mutant BTK. In addition to strong hydrogen bonding, WS-11 also forms robust π-π interactions with PHE540, and p-π interactions with LYS430 within the active pocket.Fórmula:C26H22FN9O2Cor e Forma:SolidPeso molecular:511.51BTK-IN-38
CAS:BTK-IN-38 (Example 125) is an efficacious inhibitor of BTK. It effectively suppresses the proliferation of DOHH2 and BT474 cells, with IC50 values of 114 nM and 340 nM, respectively.Fórmula:C27H26F2N4O2Cor e Forma:SolidPeso molecular:476.52RET-IN-14
CAS:RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.Fórmula:C24H23FN8O4Cor e Forma:SolidPeso molecular:506.49BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Fórmula:C26H36N6O3Cor e Forma:SolidPeso molecular:480.6UBX-382
CAS:UBX-382 is an orally administered proteolysis-targeting chimera (PROTAC) designed to target BTK and disrupt B-cell receptor signaling. It demonstrates enhanced degradation of both wild-type and mutant BTK proteins, exhibiting anti-cancer effects in murine xenograft models using TMD-8 cells [1].Fórmula:C42H44N10O4Cor e Forma:SolidPeso molecular:752.86Vecabrutinib
CAS:Vecabrutinib (SNS-062) is a potent and noncovalent BTK and ITK inhibitor (Kd: 0.3 nM and 2.2 nM, respectively). Vecabrutinib displays an IC50 of 24 nM for ITK.Fórmula:C22H24ClF4N7O2Pureza:99.74%Cor e Forma:SolidPeso molecular:529.92Ref: TM-T17220
1mg82,00€5mg177,00€1mL*10mM (DMSO)207,00€10mg289,00€25mg470,00€50mg623,00€100mg874,00€
